DiscoverAllergy/Immunology – Dr. Barry DworkinSmall in vitro study suggests two new COVID subvariants may dodge natural immunity response. However whether this translates into worsening clinical outcomes remains unanswered.
Small in vitro study suggests two new COVID subvariants may dodge natural immunity response. However whether this translates into worsening clinical outcomes remains unanswered.

Small in vitro study suggests two new COVID subvariants may dodge natural immunity response. However whether this translates into worsening clinical outcomes remains unanswered.

Update: 2022-05-04
Share

Description

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Small in vitro study suggests two new COVID subvariants may dodge natural immunity response. However whether this translates into worsening clinical outcomes remains unanswered.

Small in vitro study suggests two new COVID subvariants may dodge natural immunity response. However whether this translates into worsening clinical outcomes remains unanswered.

Dr. Barry Dworkin